Omeros Corporation (OMER) will soon begin two mid stage clinical trials on its drug OMS824 which has greatly increased its stock prices. The company is testing its drug as a treatment for Huntington’s disease toward the end of 2013 as well as trials involved the treatment of Schizophrenia. The FDA has also awarded OMS824 orphan drug status as a treatment for Huntington’s. These two neurological disorders have been diagnosed in numerous Americas. The positive outlook thus far on this drug looks promising.
Through our news, radio interviews, video production, and research, OneMedPlace specializes in delivering information to investors covering nanocap, microcap and private emerging growth companies in the hottest areas of life sciences. OneMedPlace covers what we believe to be an undervalued sector, and has built a network of investors at all levels of financial and strategic development. OneMedPlace produces two investor conferences, OneMedForumSF in January and OneMedForumNY in June, bringing together our diverse network to meet the most promising companies in life sciences. Visit our website to learn more about attending.